What is DBV Technologies's stock issuance proceeds?

DBV Technologies (DBVT) reported stock issuance proceeds of $89.1M in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

DBV Technologies DBVT Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Avalo TherapeuticsAVTX

$2.18M—

Cullinan Therapeutics, Inc.CGEM

$0-100%

Celldex TherapeuticsCLDX

$327K+61.9%

Nektar TherapeuticsNKTR

$1.07B+506,582%

Kymera TherapeuticsKYMR

$19.19M—

Alumis Inc.ALMS

$323.8M+264,765%

Other financials

Income statement

See full

Revenue$900.0K+12.5%

Operating income-$47.9M-80.1%

Net income-$47.6M-75.6%

EPS (diluted)-$0.11+57.7%

Balance sheet

See full

Cash & equivalents$229.2M+1,668%

Total debt$6.1M-15.7%

Total equity$207.9M+7,069%

Total assets$266.4M+427%

Cash flow

See full

Operating cash flow-$49.1M-149%

CapEx$400.0K—

Free cash flow-$49.5M-151%

Valuation

See full

Market cap$923.31M+269%

Enterprise value$700.21M+188%

P/S159.6×+89.0×

Profitability

See full

Operating margin-2,910.4%-265pp

Net margin-2,895.4%-257pp

FCF margin-2,619.5%+69.9pp

Returns & leverage

See full

Return on equity-158.9%-26.4pp

Debt / equity0×-2.5×

Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOrSaleOfEquity.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is DBV Technologies's stock issuance proceeds?: DBV Technologies (DBVT) reported stock issuance proceeds of $89.1M in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.